Literature DB >> 8724429

The effects of prefrontal intracortical microinjections of an alpha-2 agonist, alpha-2 antagonist and lidocaine on the delayed alternation performance of aged rats.

H Tanila1, P Rämä, S Carlson.   

Abstract

A selective alpha-2 agonist medetomidine, a selective alpha-2 antagonist atipamezole and lidocaine were injected into the prefrontal cortex of aged rats that had been trained to perform a delayed alternation (DA) task in a T maze. Medetomidine at the dose of 0.01 microgram/microliter improved the memory task performance in four of five rats. The fifth rat improved its performance at the dose of 1.0 microgram/microliter. Atipamezole did not have any effect on the task performance. The effect of a systemic dose of medetomidine (3 micrograms/kg), which was previously shown to improve the task performance in old rats, was reversed by an intracortical injection of atipamezole. Lidocaine impaired the DA performance significantly. The results suggest that the beneficial effects of medetomidine on the working memory of old rats are mediated at least partly through the prefrontal cortex.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8724429     DOI: 10.1016/0361-9230(96)00026-3

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  20 in total

Review 1.  Adrenergic pharmacology and cognition: focus on the prefrontal cortex.

Authors:  Brian P Ramos; Amy F T Arnsten
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

Review 2.  Molecular modulation of prefrontal cortex: rational development of treatments for psychiatric disorders.

Authors:  Nao J Gamo; Amy F T Arnsten
Journal:  Behav Neurosci       Date:  2011-06       Impact factor: 1.912

Review 3.  Noradrenergic modulation of working memory and emotional memory in humans.

Authors:  Samuel R Chamberlain; Ulrich Müller; Andrew D Blackwell; Trevor W Robbins; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2006-04-27       Impact factor: 4.530

4.  Effects of clonidine in the locus coeruleus on prefrontal- and hippocampal-dependent measures of attention and memory in the rat.

Authors:  Robert D Mair; Yueping Zhang; Kathleen R Bailey; Margaret M Toupin; Robert G Mair
Journal:  Psychopharmacology (Berl)       Date:  2005-04-14       Impact factor: 4.530

5.  Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: altered working memory and BOLD response.

Authors:  Thomas W McAllister; Brenna C McDonald; Laura A Flashman; Richard B Ferrell; Tor D Tosteson; Norman N Yanofsky; Margaret R Grove; Andrew J Saykin
Journal:  Int J Psychophysiol       Date:  2011-07-19       Impact factor: 2.997

Review 6.  Prefrontal cortex and drug abuse vulnerability: translation to prevention and treatment interventions.

Authors:  Jennifer L Perry; Jane E Joseph; Yang Jiang; Rick S Zimmerman; Thomas H Kelly; Mahesh Darna; Peter Huettl; Linda P Dwoskin; Michael T Bardo
Journal:  Brain Res Rev       Date:  2010-09-15

Review 7.  The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex.

Authors:  Robert C Spencer; David M Devilbiss; Craig W Berridge
Journal:  Biol Psychiatry       Date:  2014-09-28       Impact factor: 13.382

8.  Selective suppression of excitatory synapses on GABAergic interneurons by norepinephrine in juvenile rat prefrontal cortical microcircuitry.

Authors:  H-X Wang; B D Waterhouse; W-J Gao
Journal:  Neuroscience       Date:  2013-05-14       Impact factor: 3.590

Review 9.  Adrenergic targets for the treatment of cognitive deficits in schizophrenia.

Authors:  Amy F T Arnsten
Journal:  Psychopharmacology (Berl)       Date:  2003-12-19       Impact factor: 4.530

10.  Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine.

Authors:  Jenna S Franowicz; Lynn E Kessler; Catherine M Dailey Borja; Brian K Kobilka; Lee E Limbird; Amy F T Arnsten
Journal:  J Neurosci       Date:  2002-10-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.